AvePoint (Nasdaq: AVPT, SGX: AVP), the global leader in data security, governance, and resilience, today announced its listing on the Main Board of the Singapore Exchange Securities Trading Limited (SGX) under the symbol “AVP.”
AvePoint Announces Dual Listing on the Singapore Exchange to Continue Global Expansion Read More »
Debut, the biotech beauty leader, has secured $20M in investment to accelerate the expansion of its proprietary, AI-based ingredient discovery platform to advance skin longevity innovation and scale its formulation business in the US and Asia.
Singapore – July 30, 2025 – Hydroleap, a pioneering company in sustainable water treatment technologies, has successfully raised an additional USD 4.75 million in its latest funding round from strategic investors including EDBI, which operates under SG Growth Capital – the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore, Antares Ventures and Woh Hup, bringing its total funding to nearly USD 12 million till date.
Augmentus, the developer of an intelligent no-code robotics solution, announced today that it has raised USD $11 million (SGD $14 million) in a Series A+ funding round. The funds will be used to accelerate regional deployment of its fully autonomous robotic surface finishing and welding systems, fulfill demand from marquee manufacturing customers, and advance R&D into hyper-adaptive, AI-driven robotic systems built for the factory floor.
Tacta Systems, a robotics company developing dextrous intelligence to give robots human-level tactile skills and spatial awareness, today announced $75 million in funding to accelerate the development of robotic solutions capable of performing complex, human-like tasks.
Tacta Systems Announces $75 million in Funding to Bring Dextrous Intelligence to Robot Read More »
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the successful completion of US$45 million Series B financing.
Over the past three decades, EDBI and SEEDS have played a foundational role in advancing Singapore’s innovation economy — from anchoring global technology leaders to nurturing promising local startups.
SG Growth Capital Quarterly, April 2025 Read More »
Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.
Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.
